Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood Cancer JournalOpen Access

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSagar LonialCBCatriona ByrneKSKaveri Suryanarayan

Discussion

Loading...

Member takes

Overview

Final analyses show ixazomib improves PFS in patients with NDMM, highlighting challenges in demonstrating OS benefit.

Key Points

  • To evaluate overall survival outcomes from the TOURMALINE-MM3 and -MM4 trials for ixazomib maintenance in NDMM.
  • Phase 3 RCTs evaluating ixazomib vs placebo in post-transplant and transplant-ineligible patients.
  • Patients received ixazomib maintenance for ≤26 cycles or until disease progression/toxicity.
  • Randomization was 3:2 between ixazomib maintenance and matching placebo.
  • Median OS not reached in TOURMALINE-MM3; MM4 showed 64.8 months for ixazomib vs 69.5 months for placebo.
  • No significant OS differences in either trial (p = 0.850 in MM3, p = 0.473 in MM4).
  • Low incidence of new primary malignancies and no new safety signals were noted.

Cite This Study

Lonial et al. (2025) studied this question.

synapsesocial.com/papers/693624a44fa91c937236c3f2https://doi.org/10.1038/s41408-025-01411-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Marginal Structural Models and Causal Inference in Epidemiology2000 · 5,692 citations